Bolt Biotherapeutics, Inc.

Insmed Incorporated , Structure Therapeutics, Inc. and Merus N.V. raised more than $1.5bn combined in recent follow-on public offerings (FOPOs), taking advantage of a spike in investor interest an

Antibody-drug conjugates are set to take make their presence felt at the upcoming American Society for Clinical Oncology (ASCO) congress in Chicago, pre-publication of the abstracts suggests. Interest

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

Biopharmaceutical companies continue to reveal restructuring plans and job cuts even as valuations overall are improving, with many second quarter earnings calls revealing a wave of actions aimed at c